Journal article
Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice
Abstract
PurposeREASSURE is a global, prospective, non-interventional study to assess long-term safety of radium-223 in patients with bone metastatic castration-resistant prostate cancer. Here we report an interim analysis of patients according to previous use of chemotherapy.MethodsRadium-223 was administered in routine clinical practice. Interim safety analysis was planned after enrolment of the first 600 patients. Patient characteristics and safety …
Authors
Dizdarevic S; Petersen PM; Essler M; Versari A; Bourre J-C; la Fougère C; Valdagni R; Paganelli G; Ezziddin S; Kalinovský J
Journal
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 46, No. 5, pp. 1102–1110
Publisher
Springer Nature
Publication Date
May 2019
DOI
10.1007/s00259-019-4261-y
ISSN
1619-7070